Soligenix Inc
SNGX3.030USD
+0.290+10.58%
交易中 （美东）报价延迟15分钟
9.65M总市值
亏损市盈率 TTM
关于 Soligenix Inc 公司
Soligenix, Inc. 是一家后期生物制药公司，专注于开发和商业化用于治疗罕见疾病的产品，这些疾病存在未满足的医疗需求。其专业生物治疗部门正在开发并专注于 HyBryte（拟定名称为 SGX301）的商业化，这是一种新型光动力疗法 (PDT)，利用安全的可见光激活局部合成金丝桃素来治疗皮肤 T 细胞淋巴瘤 (CTCL)。该部门的开发计划还包括将合成金丝桃素 (SGX302) 扩展到牛皮癣和将 dusquetide (SGX942 和 SGX945) 扩展到治疗炎症性疾病。其公共卫生解决方案部门包括 RiVax（其蓖麻毒素候选疫苗）和 SGX943（其抗生素耐药性和新发传染病治疗候选药物）的开发计划以及针对丝状病毒（如马尔堡和埃博拉）的疫苗计划和 CiVax（其用于预防 COVID-19 的候选疫苗）。
公司简介
公司代码SNGX
公司名称Soligenix Inc
上市日期Apr 04, 1994
CEODr. Christopher J. (Chris) Schaber, Ph.D.
员工数量14
证券类型Ordinary Share
年结日Apr 04
公司地址29 Emmons Drive
城市PRINCETON
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编08540
电话16095388200
网址https://www.soligenix.com/
公司代码SNGX
上市日期Apr 04, 1994
CEODr. Christopher J. (Chris) Schaber, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Christopher J. (Chris) Schaber, Ph.D.
Dr. Christopher J. (Chris) Schaber, Ph.D.
Chairman of the Board, Chief Executive Officer and President
Chairman of the Board, Chief Executive Officer and President
379.00
--
Dr. Jerome B. Zeldis, M.D., Ph.D.
Dr. Jerome B. Zeldis, M.D., Ph.D.
Independent Director
Independent Director
96.00
--
Dr. Richard C. Straube, M.D.
Dr. Richard C. Straube, M.D.
Senior Vice President and Chief Medical Officer
Senior Vice President and Chief Medical Officer
34.00
--
Dr. Robert Joseph Rubin, M.D.
Dr. Robert Joseph Rubin, M.D.
Independent Director
Independent Director
19.00
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Mr. Jonathan L. Guarino, CPA
Mr. Jonathan L. Guarino, CPA
Chief Financial Officer, Senior Vice President, Corporate Secretary
Chief Financial Officer, Senior Vice President, Corporate Secretary
--
--
Dr. Oreola Donini, Ph.D.
Dr. Oreola Donini, Ph.D.
Senior Vice President, Chief Scientific Officer
Senior Vice President, Chief Scientific Officer
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Christopher J. (Chris) Schaber, Ph.D.
Dr. Christopher J. (Chris) Schaber, Ph.D.
Chairman of the Board, Chief Executive Officer and President
Chairman of the Board, Chief Executive Officer and President
379.00
--
Dr. Jerome B. Zeldis, M.D., Ph.D.
Dr. Jerome B. Zeldis, M.D., Ph.D.
Independent Director
Independent Director
96.00
--
Dr. Richard C. Straube, M.D.
Dr. Richard C. Straube, M.D.
Senior Vice President and Chief Medical Officer
Senior Vice President and Chief Medical Officer
34.00
--
Dr. Robert Joseph Rubin, M.D.
Dr. Robert Joseph Rubin, M.D.
Independent Director
Independent Director
19.00
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月16日 周五
更新时间: 5月16日 周五
持股股东
股东类型
持股股东
持股股东
占比
Connective Capital Management, LLC
3.11%
Geode Capital Management, L.L.C.
0.90%
UBS Financial Services, Inc.
0.32%
Morgan Stanley Smith Barney LLC
0.11%
The Vanguard Group, Inc.
0.10%
Other
95.46%
持股股东
持股股东
占比
Connective Capital Management, LLC
3.11%
Geode Capital Management, L.L.C.
0.90%
UBS Financial Services, Inc.
0.32%
Morgan Stanley Smith Barney LLC
0.11%
The Vanguard Group, Inc.
0.10%
Other
95.46%
股东类型
持股股东
占比
Hedge Fund
3.11%
Investment Advisor/Hedge Fund
0.90%
Investment Advisor
0.54%
Individual Investor
0.02%
Other
95.43%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
50
149.55K
4.58%
-122.83K
2025Q1
50
149.55K
4.59%
-122.83K
2024Q4
62
34.48K
1.37%
-224.66K
2024Q3
62
66.84K
2.91%
-140.04K
2024Q2
61
101.18K
6.59%
-9.86K
2024Q1
57
15.87K
2.48%
-90.98K
2023Q4
55
24.60K
3.87%
-67.56K
2023Q3
57
57.20K
9.40%
-37.02K
2023Q2
61
91.32K
18.32%
+80.79K
2023Q1
62
7.29K
3.99%
-8.64K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Connective Capital Management, LLC
101.63K
3.11%
+101.63K
--
Mar 31, 2025
Geode Capital Management, L.L.C.
29.37K
0.9%
+3.27K
+12.55%
Mar 31, 2025
UBS Financial Services, Inc.
10.47K
0.32%
+10.16K
+3244.73%
Mar 31, 2025
Morgan Stanley Smith Barney LLC
3.59K
0.11%
-1.00
-0.03%
Mar 31, 2025
The Vanguard Group, Inc.
3.18K
0.1%
--
--
May 31, 2025
Schaber (Christopher J)
379.00
0.01%
--
--
Apr 21, 2025
Plante Moran Financial Advisors, LLC
300.00
0.01%
--
--
Mar 31, 2025
Morgan Stanley & Co. LLC
223.00
0.01%
--
--
Mar 31, 2025
Zeldis (Jerome B)
96.00
0%
--
--
Apr 21, 2025
Northern Trust Investments, Inc.
72.00
0%
+72.00
--
Dec 31, 2023
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Apr 29, 2024
Merger
16<1
Apr 29, 2024
Merger
16<1
Apr 29, 2024
Merger
16<1
Apr 29, 2024
Merger
16<1
Feb 09, 2023
Merger
15<1
Feb 09, 2023
Merger
15<1
公告日期
类型
比率
Apr 29, 2024
Merger
16<1
Apr 29, 2024
Merger
16<1
Apr 29, 2024
Merger
16<1
Apr 29, 2024
Merger
16<1
Feb 09, 2023
Merger
15<1
Feb 09, 2023
Merger
15<1
Feb 09, 2023
Merger
15<1
Feb 09, 2023
Merger
15<1
